Esperion Therapeutics

Allay Therapeutics Appoints Nicole Vitullo to Board of Directors

Retrieved on: 
Mercoledì, Settembre 6, 2023
Health, Surgery, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Nicole, Actavis, University, Esperion Therapeutics, Transformation/transcription domain-associated protein, MBA, Cubist Pharmaceuticals, Onyx Pharmaceuticals, Esperies, Celgene, Partner, Patient, Forest Laboratories, Arboretum, Pain management, Alexion, Jazz Pharmaceuticals, David Allais, Mathematics, Therapy, Caregiver, Pharmaceutical industry

Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the appointment of Nicole Vitullo, venture partner at Arboretum Ventures, to its board of directors.

Key Points: 
  • Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the appointment of Nicole Vitullo, venture partner at Arboretum Ventures, to its board of directors.
  • “We’re thrilled to have Nicole join the Allay board and appreciate the continued support of Arboretum Ventures as we work to change the pain management paradigm and dramatically improve the post-surgical recovery experience for patients,” said Adam Gridley, Chief Executive Officer of Allay Therapeutics.
  • Nicole currently serves on the board of Esperion Therapeutics and Hinge Bio Inc.
  • Her past board memberships include numerous companies that have entered transactions, including Achillion Pharmaceuticals (Alexion), Calixa Therapeutics (Cubist Pharmaceuticals), Celator Pharmaceuticals (Jazz Pharmaceuticals), Cerexa (Forest Laboratories), Durata Therapeutics (Actavis), Marinus Pharmaceuticals, Onyx Pharmaceuticals, and VentiRx Pharmaceuticals (Celgene).

AI Therapeutics Announces Appointment of Biotechnology Industry Leader David Scheer as Chairman of the Board of Directors

Retrieved on: 
Mercoledì, Luglio 12, 2023
Yale University, National Medal of Technology and Innovation, DNA, Bioethics, Therapy, Esperion Therapeutics, Harvard T.H. Chan School of Public Health, NORD, Biotechnology, Johnson & Johnson, NYU, Microsoft Access, National Medal, Innovation, National Organization for Rare Disorders, Harvard College, Harvard University, Esperies, Developmental Biology (journal), Public health, Investment, Patient, Initial public offering, AI, Rare, Global Virus Network, Pharmaceutical industry, Medical device, Cell, ViroPharma

GUILFORD, Conn., July 12, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the appointment of David Scheer as Chairman of the Board of Directors.

Key Points: 
  • GUILFORD, Conn., July 12, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the appointment of David Scheer as Chairman of the Board of Directors.
  • Since 1981, Mr. Scheer has provided corporate strategic and transactional advisory services to the life sciences industry as founder and President of Scheer & Company.
  • “It is with great pleasure that I welcome David Scheer as Chairman of AI Therapeutics.
  • Dr. Rothberg is a true visionary, and we are grateful for his continued involvement as a Director of the Company.”
    “It is a privilege to join the AI Therapeutics Board of Directors as Chairman,” said Mr. Scheer.

NeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors

Retrieved on: 
Venerdì, Maggio 12, 2023
Auxilium, Glucagon-like peptide-1 receptor, OXM, Union of Sales and Marketing Professionals, Medical device, Senior, International Management Institute, Bhubaneswar, NASH, Esperion Therapeutics, Marketing, Abbott Laboratories, State university system, Business, Head, Sale, Political science, Esperies, Business administration, Investigational New Drug, GCGR, New York University Stern School of Business, GPR119, GLP1R, Sales and operations planning, Fatty liver disease, Growth, Commercial, Therapy, IND, Oxyntomodulin, Student Senators Council of New York University, Endo International, Pharmaceutical industry, Management

"Mark is a highly accomplished pharmaceutical industry executive with more than 30 years of industry experience, including many senior leadership positions," said Andrew I. Koven, Chairman of NeuroBo's Board of Directors.

Key Points: 
  • "Mark is a highly accomplished pharmaceutical industry executive with more than 30 years of industry experience, including many senior leadership positions," said Andrew I. Koven, Chairman of NeuroBo's Board of Directors.
  • "I am excited to join the NeuroBo Board of Directors at such an important stage for the Company, especially during the advancement of the Company's two promising cardiometabolic assets," said Mr. Glickman.
  • "I look forward to working with my fellow Directors and the NeuroBo leadership team as we position the Company for long-term growth and value creation."
  • Prior to this role, he served as Chief Business Officer, Commercial of TherapeuticsMD, Inc. since June 2021.

RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500

Retrieved on: 
Mercoledì, Gennaio 11, 2023
North Wilkesboro Speedway, 2015 NASCAR Sprint All-Star Race, Education, Therapy, RFK, NCS, LDL, FS1, Buescher, Tasmanian association football cup competitions, Cholesterol, NBC, Cup, Esperion Therapeutics, Patient, Ford Motor Company, Esperies, FOX, Ezetimibe, Roush Fenway Racing in the NASCAR Cup Series, NASCAR, Pharmaceutical industry, Communications satellite, Nightclub, Daytona, Duel, Colosseum

6 Ford at this year’s Daytona Speedweeks, including the famed Daytona 500 on February 19.

Key Points: 
  • 6 Ford at this year’s Daytona Speedweeks, including the famed Daytona 500 on February 19.
  • “We’re thrilled to have Esperion, a company that is making waves in the pharmaceutical industry, on board with us,” said Steve Newmark, President of RFK Racing.
  • Keselowski enters his second season at RFK and 14th full season in the NASCAR Cup Series (NCS).
  • At Daytona and Michigan combined, Keselowski has 19 combined top-10 efforts, including a win in the 2022 Duels where RFK swept the season-opening exhibition qualifying races.

Catalent Announces Changes to its Board of Directors

Retrieved on: 
Lunedì, Dicembre 19, 2022
Health, Chemicals, Plastics, Manufacturing, Other Science, Science, Pharmaceutical, Biotechnology, Boehringer Ingelheim, Patient, Female, Merck, NYSE, Head, Information, Health, Leonard Green, Esperies, Growth, Retirement, COVID-19, CDMO, Failure, Mallinckrodt, Excipient, Therapy, Partner, CTLT, Acquisition, Leonard Green & Partners, Esperion Therapeutics, Fine chemical, Risk management, Pharmaceutical industry, Catalent, Inotek Pharmaceuticals

“On behalf of the Catalent Board of Directors and the entire company, I want to thank John for his leadership and countless contributions to our mission to help people live better and healthier lives,” said Mr. Carroll.

Key Points: 
  • “On behalf of the Catalent Board of Directors and the entire company, I want to thank John for his leadership and countless contributions to our mission to help people live better and healthier lives,” said Mr. Carroll.
  • “Rolf was a highly valued member of our board for the last eight years, and his guidance and deep industry insights have proven invaluable to Catalent’s leadership and his fellow board members.
  • Mr. Carroll has served on Catalent’s board since July 2015 and has been its lead independent director since October 2021.
  • Mr. Carroll has been chairperson of the board of directors of Esperion Therapeutics since June 2022.

Tyra Biosciences Announces Planned Chief Financial Officer Transition

Retrieved on: 
Mercoledì, Novembre 2, 2022
Security (finance), Agricultural economics, Growth, Montana State University, FGFR3, Risk, CEO, Vinylcyclopropane rearrangement, Fibroblast growth factor receptor, MicroRNA, Acquisition, U.S. Securities and Exchange Commission, Annual report, Daiichi Sankyo, FGFR, SEC, Cancer, Esperies, Research, AbbVie, FGFR4, Regeneron Pharmaceuticals, Business administration, Esperion Therapeutics, IND, Nasdaq, COVID-19, FGFR2, Agriculture, Fibroblast growth factor receptor 1, Eli Lilly, SNP, CFO, Form 10-K, RET, Sale, PricewaterhouseCoopers, Private Securities Litigation Reform Act, Achondroplasia, Transfection, Therapy, FDA, Patient, Audit committee, Cooper, Science, CA, Pharmaceutical industry, Cholangiocarcinoma

CARLSBAD, Calif., Nov. 2, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that its Chief Financial Officer, Esther van den Boom, will be stepping down to transition into an advisory role at the end of 2022. TYRA also announced that Alan Fuhrman has been appointed as Chief Financial Officer effective January 1, 2023, and Ms. van den Boom will support the transition. 

Key Points: 
  • CARLSBAD, Calif., Nov. 2, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that its Chief Financial Officer, Esther van den Boom, will be stepping down to transition into an advisory role at the end of 2022.
  • TYRA also announced that Alan Fuhrman has been appointed as Chief Financial Officer effective January 1, 2023, and Ms. van den Boom will support the transition.
  • Prior to that, Mr. Fuhrman served as the Chief Financial Officer of Amplyx Pharmaceuticals, Inc. from December 2017 through June 2020.
  • "It has been my privilege to serve as Chief Financial Officer of TYRA since shortly after the company's inception," said Ms. van den Boom.

Slone Partners Places Richard B. Bartram as Chief Financial Officer at MBX Biosciences

Retrieved on: 
Martedì, Aprile 26, 2022
People, Biotechnology, Degenerative disease, Esperies, PEPS, New Enterprise Associates, PEP, CFO, Patient, Michigan State University, LinkedIn, Growth, Precision medicine, Associate, MBX, Teriparatide, Bartram, Certified Public Accountant, Hypoparathyroidism, PricewaterhouseCoopers, Esperion Therapeutics, Therapy, Pharmaceutical industry, Management, Insulin lispro

SOUTH RIDING, Va., April 26, 2022 /PRNewswire-PRWeb/ -- Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Richard B. Bartram as Chief Financial Officer (CFO) at MBX Biosciences, a clinical stage biopharmaceutical company developing peptide therapeutics with a focus on the treatment of endocrine disorders.

Key Points: 
  • "Rick Bartram is a tremendously talented and respected business leader with an outstanding track record of success over many years," said Slone Partners CEO Leslie Loveless .
  • "He is a savvy financial strategist, operational planner, and trusted business partner, and will be a wonderful addition to the MBX executive team."
  • "I am thrilled to join MBX Biosciences at such an exciting time of opportunity for the company," said Bartram.
  • Slone Partners delivers the leaders who build amazing and diverse life sciences and healthcare organizations People Are Our Science.

Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

Retrieved on: 
Martedì, Febbraio 22, 2022
GLOBE, Risk, Development, Health, Partnership, Ezetimibe, Physician, Guideline, Population, CVD, Twitter, Growth, Security (finance), NASDAQ, Hypercholesterolemia, Atherosclerosis, Administration, Research, ESPR, COVID-19, CLEAR, Therapy, Bempedoic acid, Tablet, Clinical trial, Moyamoya disease, Stroke, Quarter, Sale, Daiichi Sankyo, Ōtsuka, U.S. Securities and Exchange Commission, Adult, Disease, MACE, Cholesterol, General officer, Forward-looking statement, Advertising, Patient, Treasury, Esperion Therapeutics, Cardiovascular disease, CEO, Mortality, Research and development, Pharmaceutical industry, Lithium, Esperies

ANN ARBOR, Mich., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.

Key Points: 
  • Royalty revenue for the fourth quarter 2021 was $0.8 million and $3.6 million for the full year ended December 31, 2021, compared to $0.2 million for the comparable periods in 2020.
  • Total revenue for the fourth quarter of 2021 was $15.4 million and $78.4 million for the full year ended December 31, 2021, compared to $9.6 million and $227.5 million for the comparable periods in 2020.
  • The decrease in the fourth quarter and full year 2021 was primarily attributable to a decrease in advertising and commercial compensation expense.
  • Esperion will host a conference call and webcast today, February 22, 2022, at 8:00 A.M. Eastern Time to discuss fourth quarter and full year 2021 financial results and provide a company update.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Venerdì, Gennaio 28, 2022
Patient, NASDAQ, General counsel, Bempedoic acid, Twitter, Cholesterol, ANN, Esperion Therapeutics, Tablet, Employment, Ezetimibe, ESPR, Health, Financial compensation, GLOBE, RSU, Pharmaceutical industry, Esperies

The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

Key Points: 
  • The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
  • The options have an exercise price of $3.65 per share, which is equal to the closing price of Esperion's common stock on January 27, 2022.
  • Esperion works hard to make our medicines easy to get, easy to take and easy to have.
  • For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc.

BioAge appoints Dov Goldstein as Chief Financial Officer and Ann Neale as Chief Development Officer

Retrieved on: 
Mercoledì, Novembre 17, 2021
Biotechnology, FDA, Managed Care, Other Health, Health, General Health, Pharmaceutical, Research, Genetics, Science, Clinical Trials, Patient, Senior, Principia, Nursing, Ageing, BS, Durata Therapeutics, CEO, Dietrich, Degenerative disease, Life, Sutro Biopharma, Population, Yale school, Partnership, MD, MBA, Pfizer, Stanford University, Columbia Business School, Leadership, University, Acorda Therapeutics, CDO, Biotie Therapies, Family, Lilly, SVP, CFO, Science, Neale, Sanofi, Esperies, Esperion Therapeutics, Kaiser Permanente, Therapy, Doctor of Philosophy, Yale School of Medicine, Biology, Pharmaceutical industry, Management

BioAge Labs, Inc., a clinical-stage biotechnology company developing medications that target the molecular causes of aging to extend healthy human lifespan, today announced the appointment of Dov Goldstein, M.D., M.B.A. as Chief Financial Officer (CFO) and Ann Neale as Chief Development Officer (CDO).

Key Points: 
  • BioAge Labs, Inc., a clinical-stage biotechnology company developing medications that target the molecular causes of aging to extend healthy human lifespan, today announced the appointment of Dov Goldstein, M.D., M.B.A. as Chief Financial Officer (CFO) and Ann Neale as Chief Development Officer (CDO).
  • We are thrilled to welcome two seasoned industry leaders into the BioAge management team, said Kristen Fortney, Ph.D., CEO of BioAge.
  • Goldstein comes to BioAge with extensive strategic financial experience in the biopharmaceutical sector.
  • He joins BioAge from Indapta Therapeutics, where he served as chief financial and business officer from 2020 to 2021 and was responsible for the companys growth strategies as well as operational finance and business development.